

Supplementary data (S1)

ROS-related gene expression profiling in MTFs after cisplatin treatment.

The gene expression of *Srxn1*, *Fmo2*, *Nqo1*, *Fth1*, *Gstp1*, *Scd1*, *Gpx3*, *Ptgs2*, *Prnp*, *ldh1*, *ApoE*, *Cyba*, *Gpx1*, *GclC*, *Gpx7*, *Hmox1*, *Gss*, *Sod2*, *Txnrd1*, *Ccs*, *PsmB5*, *Gpx5*, *Nfb*, *Txn1*, *Prdx3*, *Hspa1a*, *Gpx4*, *Ctsb*, *Txnip*, *Prdx5*, *Prdx1*, *Gclm*, *Sqstm1*, *Lpo*, *Ehd2*, *Mpo*, *Gstk1*, *Gpx6*, *Prdx2*, *Cygb*, *Sod3*, *Park7*, *Txnrd2*, *Sod1*, *Aox1*, *Serpinb1b*, *Cat*, *Fancc*, *Ift172*, *Prdx4*, *Duox1*, *Nox4*, *Il19*, *Slc38a1*, *Dnm2*, *Gpx2*, *Txnrd3*, and *Als2* in cisplatin-treated MTFs were higher than in control. The expression levels of *Ercc2*, *Crcc6*, and *Recql4* were lower in cisplatin-treated MTFs than in control. Gene expression levels are presented as log₂ value compared to the control value (log₂ O). Quantitative analysis of each protein level. Data are shown using the mean and the standard error of the mean (n = 3). Statistical significance was set at P < 0.05.

